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Melphalan remains the most widely used agent in preparative regimens for hematopoietic stem cell trans-
plantation (SCT). From its initial discovery more than 50 years ago, it has been gradually incorporated in the
conditioning regimens for both autologous and allogeneic transplantations because of its myeloablative
properties and broad antitumor effects as a DNA alkylating agent. Melphalan remains the mainstay condi-
tioning for multiple myeloma and lymphomas, and it has been used successfully in preparative regimens of
a variety of other hematological and nonhematological malignancies. The addition of newer agents to
conditioning, such as bortezomib or lenalidomide for myeloma or clofarabine for myeloid malignancies, may
improve antitumor effects for transplantation, whereas melphalan in combination with alemtuzumab may
represent a backbone for future cellular therapy because of reliable engraftment and low toxicity proﬁle. This
review summarizes the development and the current use of this remarkable drug in hematopoietic SCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Bone marrow suppression is the dose-limiting toxicity of
Melphalan was ﬁrst synthesized in 1953 by substituting
L-phenylalanine for the methyl group on nitrogen mustard
[1]. Since then, it has been used in the treatment of various
malignancies including ovarian cancer, breast cancer,
neuroblastoma, lymphomas, acute leukemias, and multiple
myeloma (MM). Because of its broad antitumor activity,
ability to ablate the bone marrow, minimal extramedullary
toxicity [2], and potent immunosuppressive effects,
melphalan found a distinctive role in autologous stem cell
transplantation (ASCT) and allogeneic stem cell trans-
plantation (allo-SCT). As a single agent, melphalanwas found
to be adequately immunosuppressive and myeloablative
allowing engraftment in allo-SCT [3]. Herein, we reviewed
the role of melphalan in stem cell transplantations (SCT) for
patients with hematological malignancies.
A detailed review of melphalan’s clinical pharmacology
can be found elsewhere [4]. Brieﬂy, melphalan is a dialkylat-
ing agentwith 2 alkyl groups. It is not cell-cycle speciﬁc and is
transported into cells by amino acid transport systems [5]. In
plasma, up to 90% of melphalan is bound to plasma proteins
[6], whereas penetration into cerebrospinal ﬂuid is low [7,8].
Melphalan is eliminated by spontaneous chemical hydrolysis
and renal excretion, which may involve active renal tubular
secretion in addition to glomerular ﬁltration [6,9]. Although
variable, melphalan’s biological half-life is approximately 60
minutes, allowing infusion of stem cells within 8 hours of
melphalan administration [10-12]. Its clearance is inﬂuenced
by the creatinine clearance, fat freemass, andhematocrit [13].
However, towhat extent renal dysfunction inﬂuences efﬁcacy
and toxicity of melphalan remains unclear. At least in one
study, renal insufﬁciency was found to increase melphalan-
induced myelosuppression [14].edgments on page 352.
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12.08.011melphalan. Although it is considered to be myeloablative at
doses of 140 mg/m2 and above [4,15], neutrophil recovery is
accomplished within 30 days of 140 mg/m2 melphalan in
most patients even without stem cell support [16]. With
stem cell support, its dose-limiting toxicity is mucositis [17].
Administration of ice chips before, during, and after
melphalan administration may decrease the severity of
mucositis by vasoconstriction and decreased blood ﬂow to
mucosae [18]. Furthermore, amifostine, a cytoprotective
agent, may decrease the severity of mucositis and allow
higher doses of melphalan to be given before transplantation
[19]. Other adverse effects of melphalan include nausea,
vomiting, diarrhea [20], alopecia [21], transaminitis [22], and
interstitial pneumonitis [23]. Cardiac arrhythmias have also
been observed with greater incidence after administration of
higher doses of melphalan, although its causality remains
unclear [19,24].
As an alkylating agent, melphalan is recognized as being
carcinogenic. Long-term risk of secondary leukemia/myelo-
dysplastic syndrome after ASCT with melphalan-containing
regimens may be as high as 7% [25]. However, because of
the scant number of long-term studies evaluating the risk of
secondary malignancies posttransplantation and frequent
utilization of melphalan with other agents in conditioning, it
is difﬁcult to estimate the relative increase, if any, in cancer
incidence posttransplantation attributed to melphalan.
Moreover, leukomogenesis because of pretransplantation
chemotherapy may be more substantial than that because of
the conditioning regimen, further diluting the accuracy of
the risk estimates [26].MM
Myeloma has been the most common indication for
melphalan conditioning in transplantation. Despite the
advent of novel myeloma agents, MM remains an incurable
disease, and ASCT is generally recommended for all eligibleTransplantation.
Table 1
Studies Comparing High-Dose Melphalan and Autologous SCT with Chemotherapy for MM
Reference No. Treatment Response EFS* OS* Notes
Attal et al.
[31]
200 VMCP/BVAP vs MEL140 + TBI
(8 Gy)
IFN-a maintenance until relapse
ASCT vs chemo
CR 22% vs 5%
VGPR 16% vs 9%
P < .001
ASCT vs chemo
27 vs 18 mo
P ¼ .01
ASCT vs chemo
NR vs 37.4 mo
P ¼ .03
Child et al.
[32]
407 BCAM vs VMCP/ Cy + G-CSF
mobilization/ MEL200
IFN maintenance in both groups
N ¼ 8 received TBI + MEL140
ASCT vs chemo
CR rate 44% vs 8%
P < .001
PR rate 42% vs 40%
P ¼ .72
PFS
ASCT vs chemo
31.6 mo vs 19.6 mo
P < .001
ASCT vs chemo
54.1 mo vs 42.3 mo
P ¼ .04
17% of patients in
chemotherapy arm
crossed over to ASCT
arm, usually after
disease progression,
hence, the actual
survival beneﬁt may
be higher
Fermand et al.
[33,35]
179 VAMP vs lomustineVP-16 +
Cy + MEL140 + TBI (1200 cGy) &
ASCT
IFN offered to both groups in
remission
Early ASCT vs
chemo
CR
18% vs 5%
Early ASCT vs
chemo
39 mo vs 13 mo
Early ASCT vs
chemo
64.6 mo vs 64 mo
P ¼ .92
Late ASCT offered to
chemotherapy group
at progression or
resistant disease after
6 cycles of VMCP.
Distribution of periods
spent without
chemotherapy was longer
in early ASCT group.
Bladé et al.
[34]
186 VBMCP/VBAD vs MEL200 or
MEL140 + TBI (12 Gy)
Responding patients in both
groups received maintenance
with IFN + Dex
until relapse
ASCT vs chemo
CR
30% vs 11%
P ¼ .002
PFS
ASCT vs chemo
42 mo vs 33 mo
P ¼ .57
ASCT vs chemo
61 mo vs 66 mo
P ¼ .89
Only patients with chemo-
sensitive disease were
enrolled.
Fermand et al.
[33,35]
190 VMCP vs CHOP + G-CSF for
collection/ VAMP/ MEL200
or MEL140 + Bu
IFN-a proposed to both arms
ASCT vs chemo
CR + MRD
36% vs 19.8%
ASCT vs chemo
25.3 mo vs 18.7 mo
P ¼ .07
ASCT vs chemo
47.8 mo vs 47.6 mo
P ¼ .91
TwiSTT
ASCT vs chemo
25.1 mo vs 16.6 mo
P ¼ .033
Barlogie et al.
[30,36,38]
516 MEL140 + TBI (12 Gy) vs VBMCP
Responding patients randomized
to IFN  4 yrs vs Obs
ASCT vs chemo
CR 11% vs 11%
ASCT vs chemo
17% vs 14%
ASCT vs chemo
38% vs 38%
SCT indicates stem cell transplantation; MM, multiple myeloma; EFS, event-free survival; OS, overall survival; V, vincristine; M, melphalan; C & Cy, cyclo-
phosphamide; P, prednisone; BVAP, carmustine, vincristine, adriamycin, and prednisone; MEL, melphalan; TBI, total body irradiation; IFN-a, interferon-alpha;
ASCT, autologous stem cell transplantation; CR, complete remission; VGPR, very good partial response; NR, not reached; BCAM, carmustine, cyclophosphamide,
adriamycin, and melphalan; G-CSF, granulocyte-colony stimulating factor; PR, partial remission; PFS, progression-free survival; VBMCP, vincristine, carmustine,
melphalan, cyclophosphamide and prednisone; VBAD, vincristine, carmustine, adriamycin, and dexamethasone; Dex, dexamethasone; CHOP, cyclophospha-
mide, adriamycin, vincristine, and prednisone; VAMP, vincristine, adriamycin, melphalan, and prednisone; Bu, busulfan; MRD,minimal residual disease; TwiSTT,
the period of time without symptoms, treatment, and treatment toxicity; Obs, observation.
* Median values.
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use of melphalan for patients with MM in 1958. Six patients
were treated, and considerable reduction in the tumor size
was observed in 3 of these patients. The earliest report of
high-dose melphalan therapy followed by autologous stem-
cell rescue for patients with myeloma came from McElwain
and Powles in 1983 [29], who treated a 34-year-oldmanwith
plasma cell leukemia with melphalan 140 mg/m2, leading to
complete remission (CR). Subsequently, Selby et al. [21] re-
ported their experience of high-dosemelphalan (140mg/m2)
therapy for 58 patients with myeloma. The median time to
leukocyte and platelet recovery in previously untreated
patients was 28 and 24 days, respectively. A CR rate of 27%
was achieved in previously untreated patients. However, 17%
of patients diedwithin the ﬁrst 2months because of sepsis or
bleeding, and almost all patients relapsed after a median
duration of remission of 19 months. In 1986, Barlogie et al.
[30] from MD Anderson Cancer Center (MDACC) reported
their experience with high-dose melphalan for treatment
of 23 patients with refractory myeloma. Sixteen patients
received a dose of 80 to 100 mg/m2, and 7 were given
140 mg/m2 followed by autologous marrow infusion.
Although the tumor mass was reduced by more than 75% in
14 patients, 6 melphalan-related deaths occurred in patients
who did not receive autologous stem cell support. Despitehigher doses of melphalan, minimal leukocyte recovery to at
least 200/mL occurred signiﬁcantly faster andmore uniformly
in patients who received autologous stem cell support.
Furthermore, only one melphalan-related death was
encountered in this group.
Single Autologous Stem Cell Transplantation
High-dose therapy with melphalan and ASCT for MMwas
associated with improved CR rates and prolongation of
overall survival (OS) [31,32]. This was ﬁrst demonstrated by
Attal et al. [31], who randomized 200 previously untreated
patients with myeloma under the age of 65 to undergo either
conventional chemotherapy or high-dose melphalan therapy
and ASCT. Patients randomized to high-dose therapy had
a signiﬁcantly higher CR rate, event-free survival (EFS), and
OS (Table 1). In 1998, Fermand et al. [33] reported the results
of a randomized trial of early ASCT vs ASCT performed after
relapse. The OS was similar in both groups; however, the
investigators favored early ASCT because it was associated
with a shorter duration of chemotherapy and better quality
of life. The survival advantage with high-dose melphalan
therapy was later conﬁrmed in another study by Child et al.
[32], in which melphalan 200 mg/m2 followed by ASCT was
associated with a signiﬁcantly higher CR rate, OS, and
progression-free survival (PFS). However, several subsequent
Table 2
Studies Comparing Single Autologous SCT with Tandem Autologous SCT for MM
Reference No. Regimen Response EFS OS Comments
Barlogie et al.
[30,36,38]
123 EDAP/MEL200
MEL200
or MEL140 þ TBI
(1125 Gy) vs chemo*
IFN-a maintenance
until relapse
PR
Tandem ASCT vs
chemo*
86% vs 52%
P ¼ .0001
Tandem ASCT vs
chemo*
Median EFS
49 mo vs 22 mo
P ¼ .0001
Tandem ASCT vs
chemo*
Median OS
62 mo vs 48 mo
P ¼ .01
Absence of abnormalities of
chromosome 11q and 13
associated with signiﬁcantly
poor EFS and OS.
Attal et al. [31] 399 MEL140 þ TBI (8 Gy) vs
(tandem arm)
MEL140 then MEL140 þ
TBI (8 Gy)
Both groups received
IFN-a maintenance
CR þ VGPRy
Single vs tandem
49% vs 63%
P ¼ .01
At 7 years
Single vs tandem
10% vs 20%
P ¼ .03
At 7 years
Single vs tandem
21% vs 42%
P ¼ .01
Median time between ﬁrst and
second ASCT was 2.5 mo.
Cavo et al.
[39,58]
321 MEL200 vs MEL200
MEL120 þ Bu
IFN-a maintenance until
relapse in both groups
Single vs tandem
nCR
33% vs 47%
P ¼ .008
Single vs tandem
median EFS
23 mo vs 35 mo
P ¼ .001
Single vs tandem
median OS
65 mo vs 71 mo
P ¼ .90
Trend for improved OS in tandem
ASCT arm in patients failing to
achieve at least nCR after ﬁrst ASCT.
(7-year rate 60% vs 47%; P ¼ .10.)
SCT indicates stem cell transplantation; MM,multiplemyeloma; EFS, event-free survival; OS, overall survival; EDAP, etoposide, dexamethasone, adriamycin, and
cisplatin; MEL, melphalan; TBI, total body irradiation; PR, partial remission; ASCT, autologous stem cell transplantation; CR, complete remission; VGPR, very
good partial response; Bu, Busulfan; nCR, near-complete remission.
* SWOG 8229 trial VMCP-VBAP & SWOG 8624 trial VMCP/VBAP vs VMCPP/VBAPP vs VAD (see Table 1 for details).
y In patients who actually underwent 1 or 2 ASCT.
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advantage for high-dose melphalan and ASCT over chemo-
therapy alone [33-36].
Recently, the landscape of myeloma treatment is
changing rapidly because of the advent of novel agents.
However, during the same time, the results of ASCT have also
improved, and the newer agents are being incorporated into
the conditioning regimens, whereas posttransplantation
maintenance strategies are being devised [37]. Until further
conclusive data become available, ASCT remains the standard
treatment of all newly diagnosed patients with myeloma
who are deemed ﬁt to undergo high-dose therapy, in most
treatment centers [37].
Tandem Autologous Stem Cell Transplantation
Barlogie et al. [38] pioneered a more intense approach
and demonstrated the feasibility of tandem ASCT with
melphalan 200 mg/m2 for the ﬁrst transplantation and
melphalan 140 to 200 mg/m2 þ total body irradiation (TBI)
for the second ASCT. Tandem ASCT was associated with
a signiﬁcantly superior CR rate, EFS, and OS compared to
chemotherapy alone (Table 2). In the Bologna 96 trial, Cavo
et al. [39] randomly assigned patients to single vs tandem
ASCT. Statistically signiﬁcant superior near-CR rates and EFS
were seen with the tandem ASCT. Although there was no
difference in OS between the 2 arms, the authors noticed that
administration of a second ASCT and the use of novel agents
for treating sequential relapses in up to 50% of patients
assigned to receive single ASCT likely contributed to pro-
longed survival duration of the entire group [39]. Further-
more, the authors noticed a trend toward improved OS in the
tandem ASCT arm in patients who failed to achieve near-CR
after ﬁrst ASCT. Recently, a meta-analysis of 6 randomized
controlled trials concluded that, although the tandem ASCT
was associated with a statistically signiﬁcant better response
rate, there was no survival beneﬁt, whereas the treatment-
related mortality (TRM) was higher with the tandem ASCT
[40]. Based on the currently available data, our approach was
to collect the stem cells for 2 ASCTs after 2 to 4 cycles of
chemotherapy, after the patient achieves remission or at the
time of maximum cytoreduction. A tandem ASCT is now
offered in the setting of a clinical trial for patients whoachieve less than very good partial response (VGPR) after the
ﬁrst ASCT.
Melphalan Dose Intensity
Melphalan at the dose 200mg/m2 is themost widely used
drug as a preparative regimen for transplantation [27]. This
regimenwas initially reported in 1992 by the Arkansas group
based on administration of 2 equally divided daily doses [41].
In a subsequent report, further dose escalation to melphalan
220 mg/m2 was studied; however, this was associated with
higher incidence of grade IV mucositis (>60%), delayed
platelet engraftment and cardiac arrhythmias [42]. In the
randomized Intergroupe Francophone du Myélome (IFM)
9502 trial [43], melphalan 200 mg/m2 was compared with
melphalan 140 mg/m2 plus 8 Gy TBI before ASCT for newly
diagnosed patients with myeloma. Melphalan 200 mg/m2
was associated with faster hematologic recovery, less trans-
fusion requirement, and shorter duration of hospitalization.
Whereas the EFS was similar, the 45-month survival rate was
signiﬁcantly superior in the melphalan 200 mg/m2 arm
(65.8% vs 45.5%; P ¼ .05). In another randomized trial,
Palumbo et al. [44] compared 2 ASCTs after melphalan
200 mg/m2 or melphalan 100 mg/m2. The OS was similar;
however, the median PFS was signiﬁcantly better in the
higher-dose arm (31.4 vs 26.2 months; P ¼ .01). Median time
to progression was also longer with melphalan 200 mg/m2
(34.3 vs 27.0 months; P ¼ .014).
Whether elderly patients, particularly those above age 70,
should receive standard dose melphalan at 200 mg/m2 or
lower doses remains unclear. In the IFM 99-06 study [45], in
which patients (65 to 75 years) were randomized to treat-
ment with melphalan, prednisone, and thalidomide vs MP vs
tandem ASCT using melphalan 100 mg/m2, PFS and OS were
found to be signiﬁcantly longer in the melphalan, predni-
sone, and thalidomide arm. It is possible that the melphalan
100 mg/m2 dose was less than optimally effective before
ASCT and might have compromised the treatment outcomes.
On the other hand, the Mayo Clinic group [46] compared 33
patients 70 years undergoing high-dose melphalan at
200 mg/m2 with a cohort of matched patients 65 years.
Dose reduction to 140 mg/m2 was required in 10 patients in
the elderly group; however, there was no difference in the
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melphalan 200 mg/m2. In another report, melphalan
200 mg/m2 was associated with excessive early mortality of
16% in patients 70 years old [47]. We have previously re-
ported that melphalan 200 mg/m2 can be safely adminis-
tered in patients older than 70 years old; however, the
incidence of cardiac and gastrointestinal toxicity may be
higher compared with intermediate-dose melphalan [48].
There are limited data on adjusting the melphalan dose
based on renal function. First, the Arkansas group showed
that ASCT with high-dose melphalanwas feasible in patients
with severe renal failure [49]. Melphalan clearance was not
signiﬁcantly delayed in patients with renal insufﬁciency, and
melphalan was not detected in the dialysate of patients who
underwent dialysis 6 hours after its infusion. The same group
later reported that, although the EFS and OS were similar in
patients with renal insufﬁciency who received melphalan
200 mg/m2 or 140 mg/m2, the gastrointestinal adverse
effects, atrial dysrhythmias, pulmonary complications, and
neurological complications were more frequent in the
higher-dose group [50]. Thirty-eight patients on dialysis
were dialyzed before melphalan infusion, and dialysis
dependence did not affect survival. A retrospective analysis
of dialysis-dependent patients and those without renal
insufﬁciency who underwent ASCT with melphalan 100 mg/
m2 and 200 mg/m2 did not reveal any signiﬁcant difference
in toxicity or survival [51]. We have previously reported that
melphalan 200 mg/m2 may not be associated with an
increase in toxicity or TRM, and renal function may actually
improve after ASCT in a subset of patients [52].
Our current standard approach for ASCT in patients with
MM is to use melphalan 200 mg/m2 except in those older
than age 70 and those with serum creatinine levels above 2.0
mg/dL or on hemodialysis, for whom a lower dose of
melphalan is used (140 mg/m2), if the patient is otherwise
eligible for transplantation. Targeting exposure to melphalan
by using the area under the curve in the latter setting
becomes particularly appealing, as recently reported [53].
Role of Induction Regimen
A strong association between maximal response after
induction therapy and long-term outcome after ASCT has
been shown [54,55]. Accordingly, the advent of novel anti-
myeloma agents and their inclusion in induction regimens
led to improved postinduction and posttransplantation
response rates compared to induction with vincristine/
doxorubicin/dexamethasone chemotherapy [56,57]. The
combination of bortezomib, thalidomide, and dexametha-
sone (BTD) was found to further improve response rates
compared to thalidomide and dexamethasone (TD) [58].
Recently, in a randomized phase III trial, BTD was shown to
be superior to TD and the combination of alkylator-based
chemotherapy and bortezomib in both response rates and
PFS [59]. CR was achieved postinduction in 35% of patients
with BTD compared with 14% and 21% with TD and combi-
nation chemotherapy, respectively. The median PFS was also
signiﬁcantly longer with BTD at 56 months compared to<36
months with others. Although whether these improvements
in response rates and PFS would translate to OS is not clear,
we recommend bortezomib-based induction regimens in
patients with MM eligible for ASCT.
Combination with Other Agents
Combination of high-dose melphalan with TBI or other
drugs has generally failed to improve survival and wasfrequently associated with additional hematologic and non-
hematologic toxicity [31,33-35,60-62]. However, as TRM
continues to improve, it is conceivably possible that
melphalan in combination with busulfan, for example, could
eventually prove superior to melphalan alone. A study in this
regard is ongoing at MDACC.
Incorporation of novel myeloma agents into MM condi-
tioning regimens is promising. Recently, bortezomib and
melphalan were combined in a phase II IFM trial [63] and
results were compared to that in the IFM 2005-01 trial (high-
dose melphalan alone) in a matched control analysis [64]. No
toxic deaths were observed, and the CR rate was signiﬁcantly
higher in the combination arm (35% vs 11%; P ¼ .001)
regardless of the type of induction therapy used. We con-
ducted a randomized phase II trial comparing a pre-ASCT
preparative regimen of ascorbic acid, arsenic trioxide, and
high-dose melphalan, with and without bortezomib [65].
The addition of bortezomib was safe and well tolerated;
however, no signiﬁcant improvement in the CR rate, PFS, or
OS was seen. Inclusion of patients with more advanced
disease probably contributed to a lack of clinical beneﬁt
noted in our study. Overall, the combination of melphalan
and novel agents for pretransplantation conditioning seems
safe and feasible, and is an area under intense investigation.
Allogeneic Stem Cell Transplantation for MM
Allo-SCT can potentially cure MM by virtue of high-dose
chemotherapy administration, absence of tumor contami-
nation of the graft, and potential for a graft-versus-myeloma
effect [66]. The initial trials of allo-SCT for MM used intense
myeloablative conditioning regimens, mostly consisting of
TBI andmelphalan [67,68]. Despite long-term disease control
in a relatively small number of patients, TRM was unac-
ceptably high (>35%) [69]. To overcome this barrier, reduced-
intensity conditioning (RIC) regimens were developed,
which resulted in marked reduction in early mortality at the
expense of higher relapse rates [70].
In order to capitalize on the reduction of TRM with RIC
allo-SCT, a strategy of planned ASCT followed by RIC allo-SCT
was developed. Initial ASCT using melphalan 200 mg/m2
followed by RIC allo-SCT using low-dose TBI or low-dose
melphalan plus ﬂudarabine was shown to be safe and also
led to a 2-year OS exceeding 70% in some studies [71-74].
Based on these encouraging results, several prospective
randomized trials were conducted, which compared tandem
ASCT with planned ASCT followed by RIC allo-SCT [75-86]
(Table 3). Overall, 2 randomized trials have shown that
ASCT followed by RIC allo-SCT leads to superior PFS and OS
[77,80], and 1 randomized trial has shown a trend toward
superior PFS with this approach [76]. The majority of other
randomized trials showed that, although allo-SCT is associ-
ated with a superior CR rate, the PFS and OS were similar to
that seen with tandem ASCT. The lack of superiority despite
better response rates with allo-SCT can be at least partly
attributed to a higher TRM with allo-SCT. Until further data
become available, we do not recommend allo-SCT in patients
with MM outside of a clinical trial.
Amyloidosis
High-dose melphalan therapy followed by ASCT is an
effective treatment for immunoglobulin amyloid light-chain
(AL) amyloidosis. In a retrospective study including 701
consecutive new patients with AL amyloidosis, the 5-year OS
of 312 patients who started stem cell mobilizationwas found
to be 47%, whereas that of patients ineligible for ASCT was
Table 3
Randomized Trials Comparing Tandem Autologous SCT with Autologous Followed by Allogeneic SCT in Patients with MM
Reference No. Regimen TRM Response PFS* OS* Comments
Garban et al.
[75]
284 Initial ASCT
MEL200
Tandem ASCT
MEL200 þ Dex
OR
MEL220 þ Dex þ B-E8
allo-SCT
Bu-Flu-ATG
Tandem ASCT 5%
allo-SCT 10.9%
CR/VGPR
Tandem ASCT 51%
allo-SCT 62.2%
EFS
Tandem ASCT
30 mo
allo-SCT
25 mo
P ¼ .56
Tandem ASCT
41 mo
allo-SCT
35 mo
P ¼ .27
Rosiñol et al.
[76]
110 Initial ASCT VBMCP/VBAD
Tandem ASCT
MEL200 or CVB
allo-SCT
Flu þ MEL
Tandem ASCT 5%
allo-SCT 16%
P ¼ .09
CR
Tandem ASCT 11%
allo-SCT 40%
P ¼ .001
Tandem ASCT
31 mo
allo-SCT
Not-reached
P ¼ .08
Tandem ASCT
58 mo
allo-SCT
Not-reached
P ¼ .9
Plateau in PFS seen in
allo-SCT group
Bruno et al.
[77]
162 Initial ASCT
MEL200
Tandem ASCT
MEL100 - 200
Allo-SCT
TBI (200 cGy)
Tandem ASCT
2% at 2-yr
Allo-SCT
10% at 2-yr
P ¼ .09
CR
Tandem ASCT 26%
allo-SCT 55%
P ¼ .004
EFS
Tandem ASCT
29 mo
Allo-SCT
35 mo
P ¼ .02
Tandem ASCT
54 mo
allo-SCT
80 mo
P ¼ .01
On multivariate analysis
allo-SCT was associated
with longer EFS and OS
Björkstrand et al.
[80]
357 Initial ASCT
MEL200
Tandem ASCT
MEL200
allo-SCT
Flu-TBI (2 Gy)
Tandem ASCT
4% at 5-yr
allo-SCT 16% at
5-yr
P < .001
CR
Tandem ASCT
41%
allo-SCT
51%
P ¼ .020
At 60-mo
Tandem ASCT
18%
allo-SCT
35%
P ¼ .001
At 60-mo
Tandem ASCT
58%
allo-SCT
65%
P ¼ .006
On intention-to-treat
analysis of high-risk
patients, allo-SCT was
associated with longer
PFS and OS
Krishnan et al.
[84]
710 Initial ASCT
MEL200
Tandem ASCT
MEL200 (patients were
then randomized to
maintenance therapy
with thalidomide þ
Dex or observation)
allo-SCT
TBI (2 Gy)
Tandem ASCT
4% at 3-yr
allo-SCT
11% at 3-yr
P < .0001
CR
Tandem ASCT 45%
allo-SCT
58%
P ¼ .007
At 3-yr
Tandem ASCT
46%
allo-SCT 43%
P ¼ .67
At 3-yr
Tandem ASCT
80%
allo-SCT 77%
P ¼ .191
Lokhorst et al.
[85]
260 Initial ASCT
MEL200 (followed by
maintenance therapy
with IFN or thalidomide.
Three patients received
tandem ASCT).
allo-SCT
TBI (2 Gy)
No donor 3%
Donor available
16%
P < .001
CR
No donor 37%
Donor available
43%
P ¼ .67
At 6-yr
No donor 22%
Donor available
28%
P ¼ .17
At 6-yr
No donor 55%
Donor available
55%
P ¼ .72
Cumulative incidence of
relapse at 6 yr was
signiﬁcantly lower in
patients with a donor vs
no donor group (55% vs
77%; P ¼ .005).
Knop et al.
[86]
199 Initial ASCT
MEL200
Tandem ASCT
MEL200
allo-SCT
Flu þ Mel þ ATG (for
unrelated donors)
- CR
Tandem ASCT 32%
allo-SCT 59%
P ¼ .003
At 3-yr
Tandem ASCT
72%
allo-SCT 60%
P ¼ .22
SCT indicates stem cell transplantation; MM, multiple myeloma; TRM, treatment-related mortality; PFS, progression-free survival; OS, overall survival; ASCT,
autologous stem cell transplantation; MEL, melphalan; Dex, dexamethasone; allo-SCT, allogeneic stem cell transplantation; Bu, busulfan; Flu, ﬂudarabine; ATG,
antithymocyte globulin; CR, complete remission; VGPR, very good partial remission; EFS, event-free survival; VBMCP, vincristine, carmustine, melphalan,
cyclophosphamide and prednisone; VBAD, vincristine, carmustine, adriamycin, and dexamethasone; CVB, cyclophosphamide, etoposide; TBI, total body irra-
diation.
CR rate for tandem ASCT: CVB 3%, Mel 35%, P < .001.
* Median PFS and OS, unless speciﬁed otherwise.
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cardiac-related. Patients who received melphalan 200
mg/m2 had a better outcome compared with patients who
received modiﬁed doses (100 or 140 mg/m2), with a 5-year
OS rate of 61% vs 41%, respectively (P < .001). Similar
results were seen in another large series in which 421
patients received high-doses (55%) or modiﬁed doses (45%)
of melphalan followed by ASCT [88]. Although the higher-
dose melphalan may be more effective, the TRM was
generally higher than that seen in patients with myeloma.
Consequently, a risk-adapted approach was evaluated in
a phase II trial in which 45 patients with newly diagnosed AL
amyloidosis involving 2 organ systems were assigned tomelphalan 100 mg/m2, 140 mg/m2, or 200 mg/m2 stratiﬁed
based on age, cardiac involvement, and renal function [89].
Only 2 patients (4.4%) had deaths attributable to stem cell
mobilization and/or transplantation. Hematological
response was seen in 63% with stable disease in another 37%
patients. Twenty patients (44%) had improvement in their
primary involved organ. No signiﬁcant difference was seen in
response rates for different melphalan doses suggesting that
a dose-adaptive approach may not be justiﬁed.
Melphalan plus dexamethasone is widely used as stan-
dard treatment for patients who are not candidates for ASCT
[90]. The response rate with this regimen, however, is low,
and CR is generally achieved in <20% of the patients [91,92].
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currently available regimens for the treatment of AL
amyloidosis [93]. However, one lingering question is
whether the patients who are selected to undergo high-dose
melphalan plus ASCT inherently have a better prognosis. In
a Mayo Clinic study, the median survival of the patients who
were eligible for ASCT but were treated with standard
chemotherapy was 42 months, which was better than the
expected median survival for all patients with AL amyloid-
osis [94]. The results were compared with a matched cohort
of patients who underwent ASCT, and no difference in
survival was seen. The authors concluded that the patients
who were eligible for ASCT represented a good-risk pop-
ulation who might have had good outcomes with chemo-
therapy alone. However, in another report from the same
group, 63 patients undergoing melphalan (100-200 mg/m2)
and ASCT were compared with 63 matched patients not
undergoing transplantation [95]. The 4-year OS was signiﬁ-
cantly superior for ASCT (70% vs 40%; P < .001). There is only
one randomized clinical trial in which high-dose melphalan
followed by ASCT was compared to chemotherapy consisting
of melphalan plus dexamethasone [96]. One hundred
patients were randomly assigned to each arm. After amedian
follow-up of 3 years, the median OS was signiﬁcantly supe-
rior in the melphalan-plus-dexamethasone arm (56.9 vs
22.2 months; P ¼ .004). However, this trial was criticized for
the high TRM of 24% with high-dose therapy, which was
higher than expected at centers performing transplantations
for AL amyloidosis [97].
Following the footsteps of myeloma treatment, in which
intensifying treatment with tandem ASCT might improve
response, Sanchorawala et al. [98] conducted a prospective
trial of tandem courses of high-dose melphalan and ASCT.
Hematologic CR was seen in 55% of patients after the initial
ASCT with TRM of 8% in the ﬁrst 100 days. A second course of
high-dose melphalan was given to 17 patients who did not
achieve CR after the initial treatment. The TRM was 6%, and
31% achieved a CR. Overall, on intention-to-treat analysis, the
CR rate was 56%. Although these results are remarkable, only
a few patients are usually ﬁt enough to undergo such intense
treatment.
Overall, we believe that ASCT has an important role in the
treatment of AL amyloidosis; however, several important
issues such as patient selection andmelphalan dose intensity
need to be addressed in prospective randomized trials.
Myeloid Malignancies
I.V. melphalan was initially evaluated in Europe in acute
myeloid leukemia (AML) treatment. At ablative doses,
melphalan followed by ASCT or in combination with TBI for
allo-SCT was associated with long-term leukemia-free
survival in more than half of the patients with AML in ﬁrst CR
[99,100]. High-dose melphalan with autologous stem cell
support was also used for patients with relapsed/refractory
AML [101].
However, it was not until the pioneering work of the MD
Anderson group using melphalan in combination with ﬂu-
darabine (FM) that melphalan found a mainstream role in
allogeneic transplantation conditioning for patients with
AML [102,103]. Fludarabine was used with melphalan
primarily because of its immunosuppressive effects [104]
and synergy with alkylating agents through inhibition of
DNA damage repair [105]. In a retrospective analysis of 112
patients with AML (n ¼ 80) or high-risk myelodysplastic
syndrome (MDS) (n ¼ 32) who underwent allo-SCT after FMconditioning at MDACC, the 2-year OS was 44% despite the
presence of active disease in 82 patients at the time of
transplantation [106]. Although the cumulative incidence of
nonrelapse mortality (NRM) for the whole cohort was 54% at
last follow-up, it was 20% at 2 years among patients in CR at
transplantation, demonstrating a relatively favorable toxicity
proﬁle. There was no difference in survival and risk of
progression between patients who received 140 mg/m2 and
180mg/m2 of melphalan as part of the conditioning regimen,
thus, 140 mg/m2 remains to this day the standard dose for
allogeneic transplantation.
To further improve regimen-related morbidity and
mortality of the FM regimen, van Besien et al. [107] incor-
porated alemtuzumab for graft-versus-host disease (GVHD)
prophylaxis in place of posttransplantation methotrexate.
Later, a retrospective comparison of patients with AML/MDS
who received the FM conditioning regimen at the University
of Chicago with alemtuzumab, and at our institutionwithout
alemtuzumab, demonstrated no difference in survival, NRM,
or relapse rate between the 2 cohorts [108]. However, GVHD
incidences were signiﬁcantly lower among patients who
received alemtuzumab.
RIC with FM may be a particularly good option for
patients with primary myeloﬁbrosis (PMF), because the
average age at PMF diagnosis is approximately 60 years
[109]. Devine et al. [110] were the ﬁrst to report the use of
FM140 in a small number of patients with myeloﬁbrosis.
Further retrospective studies demonstrated long-term
disease-free survival in patients with PMF after allo-SCT
with FM conditioning [111,112]. We recently reported our
experience in patients with PMF with leukemic trans-
formation [113]. All patients who received FM conditioning
engrafted, and all JAK2V617F mutation-positive patients
became negative on day 30 after transplantation. Approxi-
mately half of the patients survived long term, suggesting
that induction chemotherapy followed by allo-SCT with
FM140 conditioning could be an effective strategy for
patients with AML progressed from myeloﬁbrosis [113].
Apart from ﬂudarabine, melphalan was also combined
with busulfan, carmustine, TBI, and clofarabine in condi-
tioning of patients with AML before transplantation
(Table 4). Of those, clofarabine-melphalan combination is of
particular interest. Clofarabine was designed to retain anti-
tumor and immunosuppressive properties of ﬂudarabine
while providing an improved safety proﬁle [114,115]. van
Besien et al. [116] recently published the results of their
phase I-II study of clofarabine, melphalan, and alemtuzumab
conditioning in 82 patients with advanced hematological
malignancies, of whom 43 had AML or MDS. All patients
engrafted. The incidence of grade II-IV acute GVHD (aGVHD)
and chronic GVHD (cGVHD) was 22% and 5%, respectively.
Among 74 patients who received 140 mg/m2 of melphalan in
the phase II part, NRM at day 100 and 1 year were 19% and
26%, respectively. One-year OS was 59%.
In summary, ﬂudarabine-melphalan combination is an
alternative to busulfan-based conditioning regimens in
myeloid malignancies. Future studies should explore the
combination with clofarabine to enhance its antitumor
effects.
Lymphoid Malignancies
Although melphalan was not part of the conditioning
regimen used in the groundbreaking study by Philip et al.
[117], which showed superior survival with ASCT over
salvage chemotherapy in patients with chemosensitive
Table 4
Studies of Allogeneic SCT with Melphalan-Containing Preparative Regimens in Patients with AML/Myelodysplastic Syndrome (Published 2000-2011)
Author,
Publication
Year/Type
Diagnosis
and Disease
Status
Median
Age
(Range)
MRD/
MUD/
Mismatch
Preparative Regimen* GVHD
Prophylaxis
Primary
Graft
Failure (n)
GVHD
Incidence
(Acute,
Chronic)y
NRMz RIz PFS/OSz
de Lima et al.,
2004/R [155]
42 AML
(10 in CR)
20 MDS
54 (22-75) 25/29/8 Flu100-150 mg/m2 þ
MEL140-180 mg/m2
TCR/CSA þ
MTX
2 (39%, 39%) 100 d: 26%
3 yr: 39%
NA 3 yr:
32%/NA
Malladi, et al.,
2004/R [156]
12 AML
(11 in CR)
4 MDS
47 (27-66) 16/0/0 Flu150 mg/m2 þ
MEL140 mg/m2
CSA þ
MTX
1 47% (II-III),
46%
4 yr: 13% LFU:
1 pt
4 yr:
79%/79%
van Besien et al.,
2005/P [107]
41 AML
(13 in CR)
MDS (11)
52 (17-71) 23/22/7 Flu150 mg/m2 þ
MEL140 mg/m2 þ
ALE100 mg/m2
TCR 2 33%, 18% 100 d: 17%
2 yr: 33%
2 yr:
40%
2 yr:
31%/39%
Tauro et al.,
2005/R [157]
56 AML
(42 in CR)
MDS (20)
52 (18-71) 35/41/0 Flu150 mg/m2 þ
MEL140 mg/m2 þ
ALE50-100 mg/m2
CSA 4 None
(III-IV),
8 pts
100 d: 9%
1 yr: 19%
LFU:
27 pts
3 yr:
37%/41%
Nakamura et al.,
2007/R [158]
15 AML
(8 in CR)
MDS (28)
(30-71) 19/20/4 Flu125 mg/m2 þ
MEL140 mg/m2
CSA þ
MMF
(MTX for
MUDs)
None 63%,
23 pts
100 d: 27%
2 yr: 35%
2 yr:
16%
2 yr:
51%/54%
Oran et al.,
2007/R [106]
82 AML
(30 in CR)
MDS (30)
55 (22-74) 53/59/0 Flu100-150 mg/m2 þ
MEL140-180 mg/m2 
GO 2-4 mg/m2 (16) 
ATG (31 with MUD)
TCR þ
MTX
4 39%, 49% LFU: 54% 2 yr:
25%
2 yr:
NA/44%
Small et al.,
2007/P [159]x
20 AML
(1 in CR)
(Total 43)
46 (1-62) 18/25/0 Bu (serum level of
600-900 ng/mL) þ
MEL135 mg/m2 
ATG 30 mg/kg (MUDs)
TCR þ
MTX
2 24%,
11 pts
LFU: 28% LFU:
10 pts
(AML pts)
3 yr:
13%/NA
(AML pts)
de Lima et al.,
2008/P [160]
48 AML
(3 in CR)
MDS (4)
53 (13-72) 31/19/2 Flu120 mg/m2 þ
MEL140 mg/m2 
GO 2-6 mg/m2 þ
ATG (MUDs)
TCR þ
MTX
None 42%, 52% 100 d: 13%
1 yr: 29%
NA 2 yr:
NA/38%
Marks et al.,
2008/P [161]x
58 AML
(11 in CR)
MDS (23)
(Total 133)
56 (24-74) 68/59/6 Flu150 mg/m2 þ
BCNU300-400 mg/m2 þ
MEL110-140 mg/m2 
ATG (MUDs)
CSA þ
MTX or
MMF
1 23%, 33%
(ext)
100 d: 16%
5 yr: 34%
NA 3 yr:
40%/47%
(AML/
MDS pts)
Kirschbaum et al.,
2011/P [162]
16 AML
(9 in CR)
63 (31-66) 8/8/0 CLO150-200 mg/m2 þ
MEL100-140 mg/m2
CSA þ
MMF or
TCR þ
SRL
None 4 pts,
5 pts
100 d: 2 pts LFU:
2 pts
LFU:
11 pts/
12 pts
SCT indicates stem cell transplantation; AML, acute myeloid leukemia; MRD, matched related donor; MUD, matched unrelated donor; GVHD, graft-versus-host
disease; NRM, nonrelapse mortality; RI, relapse incidence; PFS, progression-free survival; OS, overall survival; R, retrospective; CR, complete remission; MDS,
myelodysplastic syndrome; Flu, ﬂudarabine; MEL, melphalan; TCR, tacrolimus; CSA, cyclosporine; MTX, methotrexate; NA, not available; LFU, last follow-up; P,
prospective; pts, patients; ALE, alemtuzumab; MMF, mycophenolate mofetil; GO, gemtuzumab ozogamicin; ATG, antithymocyte globulin; Bu, busulfan; BCNU,
carmustine; ext, extensive chronic GVHD; CLO, clofarabine; SRL, sirolimus.
* Cumulative doses shown.
y Cumulative incidences of grade II-IV acute GVHD followed by limited and extensive chronic GVHD shown unless indicated. If incidence is not available,
number of patients were shown.
z Time points shown (d: day, yr: year) before incidence. If incidence not available, number of patients was shown.
x Study including patients with diagnoses other than AML and MDS. Information given is applicable to the whole cohort unless indicated.
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porated into the probably most commonly used conditioning
regimen for patients with lymphoma today, carmustine,
etoposide, arabinoside, melphalan (BEAM; at 140 mg/m2).
BEAM, designed in the mid-80s [118,119], was favored over
carmustine, etoposide, arabinoside, cyclophosphamide in
most transplantation centers because of its simpler treat-
ment scheme. Mucositis is almost universal after BEAM
chemotherapy, commonly requiring opioids and sometimes
total parenteral nutrition [120-122]. Still, BEAM is a fairly
well-tolerated regimen with early NRM rates of less than 5%
[122-125].
ASCT with BEAM is effective in the treatment of both
chemosensitive aggressive non-Hodgkin lymphoma (NHL)
and Hodgkin lymphoma (HL). Among relapsed/refractory
aggressive chemosensitive patients with NHL, long-term OS
and PFS ranged between 56% to 64% and 49% to 51% after
ASCT with BEAM conditioning [120,122,123]. In retrospective
analyses, BEAM was also observed to be effective in the
treatment of anaplastic large cell lymphomas andangioimmunoblastic lymphomas [126,127]. As in NHL, BEAM
is highly effective in patients with chemosensitive relapsed/
refractory HL, with reported long-term OS and PFS rates of
56% to 78% and 49% to 69% [122,125,128,129].
More recently, fotemustine and bendamustine were
substituted for carmustine to improve the antitumor effect of
BEAM regimen. In a prospective study including 84 patients
with relapsed/refractory lymphoma who underwent ASCT
with the fotemustine, etoposide, arabinoside, cyclophospha-
mide regimen, 100-day NRM was 2% with 74 patients (88%)
still alive after a median follow-up of 13 months [130].
Meanwhile, in a similar study with bendamustine, etoposide,
arabinoside, and cyclophosphamide, which included 43
patients with relapsed/refractory lymphoma, none of the
patients died within 100 days of transplantation. Thirty-ﬁve
patients (81%) were still alive after a median follow-up of 18
months [131].
Melphalan was also used in combination with busulfan
before ASCT for the treatment of lymphoid malignancies.
First, Srivastava et al. [132] demonstrated the feasibility of
Table 5
Studies of Allogeneic SCT with Fludarabine-Melphalan Conditioning in Patients with Lymphoid Malignancies
Author,
Publication
Year/Type
Diagnosis and
Disease Status*
Median Age
(Range)
MRD/MUD/
Mismatch
Preparative
Regimeny
GVHD
Prophylaxis
Primary
Graft
Failure (n)
GVHD
Incidence
(Acute,
Chronic)z
NRMx PFS/OSx
Branson et al.,
2002/R [139]
10 H-NHL, 1 L-NHL,
2 MCL, 12 HL, 1 CLL,
12 MM [38]
NA 38/0/0 Flu150 mg/m2 þ
MEL140 mg/m2 þ
ALE100 mg
CSA þ MTX NA None (III-IV),
5 pts
100 d: 8%
14 mo: 20%
14 mo:
50%/53%
Morris et al.,
2004/R [163]
37 H-NHL, 41 L-NHL,
10 MCL [37]
48 (18-73) 63/17/8 Flu150 mg/m2 þ
MEL140 mg/m2 þ
ALE100 mg
CSA 1 pt 13 pts, 6 pts Early: 14 pts 3 yr:
NA/55%
Delgado et al.,
2006/P [140]
41 CLL [0] 54 (37-67) 24/13/4 Flu150 mg/m2 þ
MEL140 mg/m2 þ
ALE100 mg
CSA None 4 pts (III-IV),
13 pts
100 d: 5%
2 yr: 26%
2 yr:
45%/51%
Rodriguez et al.,
2006/R [164]
19 H-NHL, 16 L-NHL,
5 MCL [16]
NA NA Flu125 mg/m2 þ
MEL140 mg/m2
NA NA 65%, 76% 2 yr: 28% LFU:
40%/53%
Thomson et al.,
2009/P [165]
48 DLBCL [34] 46 (23-64) 29/10/9 Flu150 mg/m2 þ
MEL140 mg/m2 þ
ALE100 mg
CSA None 8 pts, 9 pts 4 yr: 32% 4 yr:
48%/47%
Alvarez et al.,
2006/P [166]
27 NS, 3 MC, 2 LD [29] 31 (16-53) 37/2/1 Flu150 mg/m2 þ
MEL140 mg/m2
CSA þ MTX 1 pt 42%, 47% 100 d: 12.5%
1 yr: 25%
2 yr:
32%/48%
Peggs et al.,
2007/R [167]
57 NS, 5 MC, 5 LP [53] 35 (19-56) 67/0/0 Flu150 mg/m2 þ
MEL140 mg/m2 
ALE100 mg
CSA  MTX 2 pts 12 pts, 20 pts NA NA
Anderlini et al.,
2008/R [141]
58 HD [48] 32 (19-59) 25/33/0 Flu125 mg/m2 þ
MEL140 mg/m2 þ
ATG
TCR þ MTX None 28%, 73% 100 d: 7%
2 yr: 15%
2 yr:
32%/64%
SCT indicates stem cell transplantation; MRD, matched related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease; NRM, nonrelapse
mortality; PFS, progression-free survival; OS, overall survival; R, retrospective; H-NHL, high- or intermediate-grade non-Hodgkin lymphoma; L-NHL, low-grade
non-Hodgkin lymphoma; MCL, mantle cell lymphoma; HL, Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NA, not available;
Flu, ﬂudarabine; MEL, melphalan; ALE, alemtuzumab; CSA, cyclosporine A; MTX, methotrexate; pts, patients; P, prospective; LFU, last follow-up; DLBCL, diffuse
large B cell lymphoma; NS, nodular sclerosing Hodgkin lymphoma; MC, mixed-cellularity Hodgkin lymphoma; LD, lymphocyte-depleted Hodgkin lymphoma;
LP, lymphocyte-predominant Hodgkin lymphoma; HD, Hodgkin disease; ATG, antithymocyte globulin; TCR, tacrolimus.
* Numbers in brackets show the number of patients who previously had autologous SCT.
y Cumulative doses shown.
z Cumulative incidences of grade II-IV acute GVHD followed by limited and extensive chronic GVHD shown unless indicated. If incidence is not available,
number of patients were shown.
x Time points shown (d: day, mo: month, yr: year) before incidence. If incidence not available, number of patients was shown.
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with a variety of malignancies. Recently, our group reported
the results from a phase II trial of pharmacokinetics-guided
i.v. busulfan and melphalan conditioning before ASCT for
patients with advanced lymphoid malignancies [133]. No
grade IV regimen-related toxicity was observed. TRM at day
100 and 3 years were 1% and 3%, respectively. Among 49 and
12 patients with Hodgkin disease (HD) and NHL beyond the
ﬁrst CR, 2-year OS rates were 85% and 67%, respectively.
To further improve its antitumor effect, our group incor-
porated gemcitabine into the i.v. busulfan and melphalan
regimen (GemBuMel). In a retrospective comparison of 115
patients with refractory HD who underwent ASCT with
BEAM (n ¼ 26), busulfan-melphalan (n ¼ 38), and GemBu-
Mel (n¼ 51) conditioning during the same period of time, no
treatment-related deaths were observed in any cohort.
Patients who received GemBuMel had a signiﬁcantly better
OS and PFS despite having worse prognostic features [134].
Our group was also the ﬁrst to demonstrate the feasi-
bility of BEAM as a preparative regimen for allo-SCT from
matched related donors in patients with NHL [135]. Subse-
quently, its feasibility was shown in patients with matched
unrelated donors and mismatched related donors with the
addition of alemtuzumab in the conditioning regimen
[136,137]. In a retrospective analysis of 65 patients with
lymphoma who relapsed or were ineligible for ASCT treated
with allo-SCT with BEAM-alemtuzumab conditioning,
Faulkner et al. [137] reported a 2-year NRM of 13%, whereas
primary graft failure occurred in 3 patients. Three-year OS
was 63%.Apart from BEAM, FM combination was also successfully
implemented for conditioning of patients with lymphoma
before allo-SCT. After the report of a case with relapsed HL
treated with allo-SCT using FM conditioning [138], Branson
et al. [139] reported on allo-SCT using FM140 in 38 patients
with lymphoproliferative malignancies, which relapsed after
ASCT. At a median follow-up of 14 months, OS, PFS, and NRM
were 53%, 50%, and 20%, respectively. Additionally, the FM
regimen with alemtuzumab was found to be effective in
patients with advanced chronic lymphocytic leukemia (CLL),
with relatively low toxicity and a PFS of 45% at 2 years [140].
Recently, Anderlini et al. [141] reported our experience with
allogeneic transplantation in patients with HL with FM
conditioning. Fifty-eight patients were treated with a day-
100 TRM of 7%. OS at 2 years and last follow-up were 64%
and 48%, despite the heavily treated cohort of patients.
Table 5 summarizes the results from studies of allo-SCT with
FM conditioning in patients with lymphoma.
Melphalan has also been used as part of conditioning for
patients with acute lymphoblastic leukemia (ALL) undergoing
allo-SCT. Deconinck et al. [142] reported on consolidation allo-
SCTwith an intensiﬁed conditioning of 12 Gy fractionated TBI,
arabinoside 3 g/m2 for 8 doses, and melphalan 140 mg/m2 in
42 high-risk patients with ALL in CR1. All but one patient
engrafted. OS and EFS at last follow-up were 45% and 40%,
similar to those reportedwith other conditioning regimensnot
containing melphalan [143,144]. RIC with FM140 was also
investigated in a prospective trial in 37 patients with high-risk
ALL in CR [145]. All patients were engrafted with 16 and 21
(76%) developing grade II-IV aGVHD and cGVHD, respectively.
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and 64%, respectively, demonstrating the feasibility of this
regimen for patients with ALL.
BEAM conditioning is still the standard of care for ASCT in
patients with lymphoid malignancies, while newer condi-
tioning regimens are being explored. For allo-SCT, BEAM and
FM regimens may be used successfully in place of TBI-based
conditioning.
Alternative Donor Transplantation
Melphalan has been incorporated into multiple RIC regi-
mens used in umbilical cord blood transplantations (UCBTs)
[146-148]. Yuji et al. [146] reported on 20 patients with
advanced lymphoma, of whom 12 had relapsed/refractory
large B cell lymphoma, who underwent single UCBT with
ﬂudarabine 25mg/m2 for 5 days, melphalan 80mg/m2, and 4
Gy TBI. Only one patient developed primary graft failure.
NRM at day 100 was relatively high at 41%, and OS and PFS at
1 year were both 50%. Recently, the Dana-Farber group re-
ported an improved NRM with FM-antithymocyte globulin
(ATG) regimen and use of double umbilical cord blood units
in 32 patients with advanced hematological malignancies
[147]. No primary graft failure was reported. Three and 4
patients experienced grade II-IV aGVHD and cGVHD. NRM at
100 days and 2 years was 13% and 34%, respectively. At
2 years, PFS and OS were 31% and 53%, demonstrating the
safety and efﬁcacy of this regimen.
Melphalan has also been used as part of conditioning
before transplantation from haploidentical related donors
(haploSCT). Lacerda et al. [149] treated 14 patients with
a regimen consisting of ﬂudarabine, melphalan, thiotepa,
cyclosporine, and rabbit ATG plus standard doses of CD34þ
selected cells. All patients engrafted, 8 developed aGVHD,
and 6 survived long term. Subsequently, Bethge et al. [150]
used the ﬂudarabine 150 to 200 mg/m2, melphalan
120 mg/m2, and thiotepa 10 mg/kg (ﬂudarabine, melphalan,
and thiotepa [FMT]) regimen in 29 patients with hemato-
logical malignancies, of whom 23 had acute leukemia. Only
one patient experienced primary graft failure. The regimen
was well tolerated with no grade 4 toxicities. The 100-day
NRM was 20% with deaths primarily because of infectious
complications related to T cell depletion. The incidence of
grade II-IV aGVHD was 48%, and 1-year OS was 35%.
We have used the FMT regimen before both UCBT and
haploSCT [151]187. In a phase II trial, 28 patients with
hematological malignancies, of whom 22 had AML/MDS,
received FMT-ATG followed by CD34þ selected grafts from
haploidentical related donors [152]. Six patients failed to
achieve primary engraftment, and 5 later received second
transplantations. Of these, 3 of 4 patients tested were found
to have anti-HLA antibodies. No grade III-IV aGVHD was
observed, and 4 patients developed cGVHD. NRM at 100
days, and last follow-up was 18% and 40%, primarily because
of infectious complications. OS at last follow-up was 18%.
More recently, we presented our early results with haploSCT
after the FMTconditioning regimen using Tcell-replete grafts
and posttransplantation cyclophosphamide [153]. Primary
engraftment was improved and achieved in 94% of patients,
TRM at 100 days was only 9%, and OS at 1 year was 66%,
demonstrating improved early outcomes with the use of
T cell-replete grafts compared to T cell-depleted haploSCT
after conditioning with the same regimen (FMT).
For alternative donor transplantations, we believe
melphalan remains the mainstay conditioning drug. For
patients with low-grade lymphoid malignancies and olderpatients with acute leukemia in remission, reduced doses of
melphalan in combinationwith ﬂudarabine and thiotepa can
be used as an alternative to ﬂudarabine-cyclophosphamide-
TBI conditioning [154].
Future Directions
In summary, since its discovery more than 50 years ago,
melphalan use has been expanded to all forms of trans-
plantation. As we move forward, this drug will likely remain
an essential component of pretransplantation preparative
regimens for autologous and allogeneic SCTandwill probably
continue to provide the framework for building newer and
better conditioning regimens in the future. Improving the
antitumor activity may prove effective by adding busulfan to
the melphalan-based conditioning for lymphoid malignan-
cies or by replacing ﬂudarabine with clofarabine for alloSCT.
Targeting melphalan dose based on area under the curve,
similar to busulfan, could be explored to maximize efﬁcacy
andminimize the toxicity of this drug. Improving relapse rate
could be also foreseen using cellular therapy after alloSCT in
patients conditioned with FM and alemtuzumab regimen, as
patients develop minimal GVHD, and immunosuppression
can be tapered early posttransplantation.
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